Akshit Chitkara, MD

105 posts

Akshit Chitkara, MD banner
Akshit Chitkara, MD

Akshit Chitkara, MD

@chitkaramd

Hematolgy-Oncology🦀Fellow at @KimmelCancerCtr TJU 2024-27 Former IM Chief Resident @UCRiverside Former California Med. Asso., Resident & Fellow Delegate

Philadelphia, Pennsylvania Tham gia Ocak 2022
235 Đang theo dõi182 Người theo dõi
Akshit Chitkara, MD
Akshit Chitkara, MD@chitkaramd·
Honored to present our latest research findings at the OncLive National Fellows Forum in San Francisco! 🌉 Grateful for the opportunity to share this work and engage with such a brilliant group of peers and mentors. #OncLive #Oncology #GUoncology
Akshit Chitkara, MD tweet media
English
0
0
2
68
Akshit Chitkara, MD
Akshit Chitkara, MD@chitkaramd·
Presenting our findings on sequential ARPI therapy in mCRPC! 🧬 So grateful to be backed by the best mentors, Dr. Zarrabi and Dr. Tester. 🙌 @ASCO
Akshit Chitkara, MD tweet mediaAkshit Chitkara, MD tweet media
English
0
0
2
106
Akshit Chitkara, MD
Akshit Chitkara, MD@chitkaramd·
Day 2 ASCO Philly starts strong with @PBarataMD spotlighting prostate cancer highlights from ASCO 2025! MMAI-driven risk stratification is making waves in prostate cancer space, promising times ahead!
Akshit Chitkara, MD tweet mediaAkshit Chitkara, MD tweet media
English
1
2
9
676
Akshit Chitkara, MD
Akshit Chitkara, MD@chitkaramd·
Kicking off ASCO Direct Philly 2025 with an excellent overview by @DrBonillaOnc, highlighting key clinical trials in the non-CRC space! Thank you @ASCO for bringing these important updates to the forefront.
Akshit Chitkara, MD tweet media
English
1
1
8
410
Akshit Chitkara, MD đã retweet
Vincent Rajkumar
Vincent Rajkumar@VincentRK·
Key Myeloma therapy update for 2025 1) Newly diagnosed: Start treatment with quads, if possible. (Dara-VRd or Isa-VRd). 2) Auto Transplant: can be deferred for standard risk patients, especially if good response to induction. But collect and store stem cells for future use. 3) Maintenance: Doublet maintenance with Dara/ Len or bortezomib/ Len for high risk myeloma. Either Single or Doublet maintenance for standard risk. 4) Use new IMWG IMS risk stratification 5) First relapse: standard triplet therapy is fine for most. CART in first relapse mainly for functional high risk (progression or early relapse with induction). 6) When using CART, disease burden should be controlled and minimal to reduce risk of serious toxicity.
Vincent Rajkumar tweet media
English
3
107
313
25.5K
Akshit Chitkara, MD đã retweet
Rohit Singh, MD
Rohit Singh, MD@RohitBanwar·
📚 Join us at #ASCO25 for Publication 101: Peer Review & Becoming a Successful Author 🗓️ June 2 | ⏰ 10:15–11:15 AM 📍Trainee & Early Career Lounge Get practical tips to boost your academic writing, peer-review & publishing success! #OncTwitter #ASCO #ASCOTECAG #UVM
Rohit Singh, MD tweet media
English
0
1
5
479
Akshit Chitkara, MD đã retweet
Udhayvir Grewal
Udhayvir Grewal@UGrewalMD·
Breaking News! (Quite literally 😍) #ASCO25 🚨 BREAKWATER trial (NEJM): EC + mFOLFOX6 sets new 1L standard in BRAF V600E-mutant mCRC ➡️OS: 30.3 vs 15.1 mo (HR 0.49, P<0.001) ➡️PFS: 12.8 vs 7.1 mo (HR 0.53, P<0.001) ⚠️ Grade ≥3 AEs: 46.1% vs 38.9% — manageable, consistent with known profiles 📄 nejm.org/doi/abs/10.105… #GIonc #mCRC #OncoTwitter #BRAF
Udhayvir Grewal tweet media
English
2
29
63
5.8K
Akshit Chitkara, MD
Akshit Chitkara, MD@chitkaramd·
Still getting asked about this key meta-analysis! 📢 In the evolving landscape of HER2-low tumors, we explored HER2-targeted treatments in HER2+ mCRC. Check it out! #GIOnc #HER2 #CRC #OncologyResearch
Akshit Chitkara, MD@chitkaramd

📢Publication alert 🚨 Excited to share our research that has been published in Current Oncology studying the efficacy of HER2-Targeted treatment regimens in HER2-Positive mCRC. mdpi.com/2470198 Special thanks to my mentor and guide Dr. @AnwaarSaeed3 for believing in me. Sincere gratitude to @IbrahimSahinMD1 @DennisJHsu @JanieYZhang @AnamikaAdib @sepideh_gholami for all the guidance and support! @UPMCHillmanCC @pitthem @UCRiverside @HemOncFellows @mdpiopenaccess @img_oncologists #GIOncology #HematologyOncology #Match2024 #Onctwitter #Medtwitter #HOfellows

English
0
0
0
232
Akshit Chitkara, MD đã retweet
Udhayvir Grewal
Udhayvir Grewal@UGrewalMD·
Great discussion on updates in anal cancer by @CathyEngMD #GI25 Anal cancer incidence rising, early stage most common. 5-year OS 36% 📌 Locally advanced anal cancer: -No role for radiosensitizing chemo- RTOG98-11, ACTII -5-FU-MMC remains SOC (cisplatin may be more appropriate in immunosupp pts, 5-FU in frail pts) -no randomized data, but cape can be considered as an alternative to 5-FU, myelosupp may be an issue. -IO in this setting-no role, ongoing studies. -no role for adjuvant or maintenance therapy. 📌Advanced anal cancer: -InterAACT: carbo-taxol became SOC due to similar ORR and better safety profile. -POD1UM-303: Retifanlimab+carbo+taxol (compared to carbo+taxol) in metastatic treatment naive metastatic anal SCC: PFS improvement, ORR 56% trend for OS improvement. HIV + pts included. Now an NCCN 2B recommendation. -EA2176: Carbo/taxol with or without Nivo- PFS primary endpoint, ctDNA incorporated. Finished enrolment. HIV+ pts included.
Udhayvir Grewal tweet mediaUdhayvir Grewal tweet media
English
1
4
6
624
Akshit Chitkara, MD
Akshit Chitkara, MD@chitkaramd·
Presented my research on Trastuzumab at OncLive National Fellows forum in San Antonio!
Akshit Chitkara, MD tweet media
English
0
0
17
755

Khám phá

@ASCO @DrArturoAI @PBarataMD @pashtoonkasi @nikhil_vojjala @vijsinghmd @ibrahimazaronc @KarmanosHemeOnc